Core Insights - The 20th Meiwos International Medical Aesthetic Conference held in Hangzhou showcased the diverse charm and profound connotations of the medical aesthetics field, featuring over 200 experts and leaders discussing topics like technological innovation and market operations [1][6] - Milan Baiyu, as the organizer, emphasized its commitment to quality medical aesthetics and its leading position in the industry, supported by 21 years of academic accumulation and a focus on technical innovation [5][6] Group 1: Conference Highlights - The conference included 16 sub-forums focusing on various aspects of the medical aesthetics industry, providing a platform for in-depth discussions and sharing of clinical experiences [1] - The standardization forum highlighted the importance of compliance and operational standards in the medical aesthetics industry, with a focus on enhancing institutional competitiveness and customer trust [2] - The cosmetic surgery forum explored collaborative mechanisms and the latest surgical techniques, addressing consumer demands for natural and personalized aesthetic procedures [3] Group 2: Key Presentations - Yao Anyan, Director of Quality Management at Langzi Medical Aesthetics, presented on the value realization of a "compliant medical aesthetics" model, emphasizing the significance of compliance for long-term institutional development [2] - Xiao Minghui, Deputy Director of Marketing at Milan Baiyu, discussed the transition from VIP to VIC personalized services, highlighting the integration of AI in the medical aesthetics service chain [3] - Wang Peng, Deputy Director of the Minimally Invasive Center, shared insights on non-surgical double eyelid techniques, addressing the diverse aesthetic needs of modern consumers [4] Group 3: Company Positioning - Milan Baiyu has established itself as a core brand under Langzi Medical Aesthetics, continuously expanding its presence with 8 hospitals across 7 cities, driven by market trends and innovative aesthetic solutions [6] - The company aims to maintain its leadership in the medical aesthetics sector by focusing on innovation and exploration, looking forward to future collaborations with the Meiwos Conference [6]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of International Medical Investment Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [1][2] - As of May 15, the company's stock closed at 5.2 yuan, down 1.33%, with a latest price-to-book ratio of 3.29 and a total market capitalization of 11.754 billion yuan [1] - The company experienced a net outflow of 6.0947 million yuan in principal funds on May 15, although it had a total inflow of 9.3634 million yuan over the past five days [1] Group 2 - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 999.7 million yuan, a year-on-year decrease of 14.99%, and a net profit of -106.35 million yuan, a year-on-year decrease of 1.37%, with a gross profit margin of 5.21% [1] - The company has received multiple honors, including being recognized as one of the "Top 100 Socially Operated Hospitals" and "Best Investor Relations Award" for 2024, indicating its reputation in the healthcare sector [1] - In comparison to industry averages, the company's price-to-earnings ratio (TTM) stands at -45.99, significantly lower than the industry average of 37.79, reflecting its current financial challenges [2]

Industry Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The medical services sector is under pressure in 2024 due to high base effects, but macroeconomic improvements are expected to drive a sustained recovery [2][5] - In Q1 2025, the demand for medical services has stabilized, leading to continuous profit improvement [3][5] - The gross profit margin has slightly declined, with 2024's margin at 37.02%, down 1.24 percentage points, and Q1 2025's margin at 36.14% [4][9] Summary by Sections 2024 Performance - The overall revenue for the medical services sector in 2024 is projected at 73.908 billion yuan, a year-on-year increase of 1.29% - The net profit attributable to shareholders is expected to be 4.857 billion yuan, a decrease of 16.37% - The net profit excluding non-recurring items is forecasted at 4.229 billion yuan, down 22.95% [2][9] Q1 2025 Performance - The total revenue for the medical services sector in Q1 2025 is 18.005 billion yuan, reflecting a year-on-year growth of 2.48% - The net profit attributable to shareholders is 1.325 billion yuan, showing a year-on-year increase of 16.24% - The net profit excluding non-recurring items is 1.266 billion yuan, up 18.21% [3][9] Profitability Metrics - The gross profit margin for 2024 is 37.02%, with a slight decline to 36.14% in Q1 2025 - The operating cash flow for Q1 2025 is 2.332 billion yuan, with a cash flow to net profit ratio of 158.22% [4][7]

Group 1 - The company will participate in the "2025 Shaanxi Listed Companies Investor Collective Reception Day and 2024 Annual Performance Briefing" to enhance communication with investors and improve investor relations management [1][2] - The event is scheduled for May 20, 2025, from 15:00 to 17:00, and will be held online via the "Panorama Roadshow" platform [1] - Key executives, including the president, vice president, board secretary, financial director, and independent directors, will engage with investors through an interactive platform [1] Group 2 - Investors are encouraged to submit questions in advance through the Panorama website, which will be addressed during the annual performance briefing [1]

证券代码：000516 证券简称：国际医学 公告编号：2025-021 西安国际医学投资股份有限公司 关于参加"2025 年陕西辖区上市公司投资者集体 接待日暨 2024 年度业绩说明会"的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 届时，公司总裁、副总裁兼董事会秘书、财务总监、独立董事及其 他相关工作人员将通过互动平台与投资者进行网络沟通和交流，欢迎广 大投资者踊跃参加！ 活动时间：2025 年 5 月 20 日（星期二）15:00-17:00 活动地址："全景路演" 网址：https://rs.p5w.net。 为充分、高效与投资者进行沟通与交流，投资者可提前登录全景网 （https://ir.p5w.net/zj）进入"业绩说明会问题征集"向公司提问， 公司将在 2024 年度业绩说明会上对投资者普遍关注的问题进行交流。 特此公告。 西安国际医学投资股份有限公司董事会 二〇二五年五月十四日 1 为促进上市公司规范运作、健康发展，增强上市公司信息透明度， 加强与广大投资者沟通交流，进一步提升投资者关系管理水平，陕西上 市公司协会在陕西证监局指导下，联 ...

Group 1: 2024 Overall Business Performance - The company achieved a total outpatient and emergency service volume of 2.5727 million, a year-on-year increase of 7.70% [1] - The inpatient service volume reached 205,700, reflecting a year-on-year growth of 10.73% [1] - The total operating revenue for the year was 4.815 billion, with a year-on-year increase of 4.28% [2] - The net profit attributable to the parent company was -254 million, a reduction in loss by 31.01% [2] Group 2: Q1 2025 Business Performance - In Q1 2025, the company reported an operating revenue of 999.7 million, a decrease of 14.99% compared to the same period last year [3] - The net profit attributable to the parent company was -106 million, a decline of 1.37% year-on-year [3] - The net operating cash flow was 244 million, indicating stable cash flow management [3] Group 3: 2024 Operational Highlights - Xi'an High-tech Hospital generated operating revenue of 1.525 billion, a year-on-year increase of 2.68% [3] - Xi'an International Medical Center Hospital achieved operating revenue of 3.274 billion, with a year-on-year growth of 7.60% [3] - The outpatient and emergency service volume at the International Medical Center Hospital reached 1.4182 million, a year-on-year increase of 18.88% [4] - The inpatient service volume was 139,700, reflecting a year-on-year growth of 15.32% [4] Group 4: Proton Center Project and Digitalization - The proton therapy center project is progressing, with the core component, the cyclotron, installed by June 18, 2024, and expected to be operational by the end of 2025 [5][6] - The company has completed local deployment of medical intelligent models, integrating with core business systems to enhance operational efficiency [7] Group 5: Quality Improvement and Service Expansion - The hospital is advancing its three-tier evaluation work, focusing on system optimization and quality enhancement [8] - The company is expanding into high-end medical services, including aesthetic medicine, rehabilitation, and proton therapy, to meet diverse health needs [9] - The company is adapting to ongoing healthcare policy reforms by refining operations and adjusting business structures to maintain service quality [10]

证券代码：000516 证券简称：国际医学 公告编号：2025-020 西安国际医学投资股份有限公司 关于控股股东进行股票质押式回购交易的进展公告 本公司及董事会全体成员保证公告内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 截至公告披露日，控股股东及其一致行动人所持质押股份情况如下： 1 股东 名称 是否为控股 股东或第一 大股东及其 一致行动人 本次质押数 量（股） 占其 所持 股份 比例 占公 司总 股本 比例 是否为 限售股 是否 为补 充质 押 质押起始 日 原质押 到期日 延期购回 后质押到 期日 质权 人 质押 用途 世纪 新元 是 19,120,000 3.10% 0.85% 否 否 2022 年 11 月 29 日 2025 年 5 月 12 日 2025 年 11 月 27 日 开源 证券 股份 有限 公司 项目 建设 资金 世纪 新元 是 46,900,000 7.61% 2.07% 否 否 2023 年 11 月 13 日 2025 年 5 月 12 日 2026 年 5 月 12 日 开源 证券 股份 有限 公司 项目 建设 资金 一、控股股东股份质押延期购回的基本情 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of International Medical Investment Co., Ltd, including its recent stock performance and institutional holdings [1][2] - As of May 13, the stock price of International Medical closed at 5.29 yuan, with a 2.52% increase, and a market capitalization of 11.957 billion yuan [1] - The company reported a revenue of 999.7 million yuan for Q1 2025, reflecting a year-on-year decrease of 14.99%, and a net profit loss of approximately 106.35 million yuan, with a gross margin of 5.21% [1] Group 2 - The company has a price-to-earnings (PE) ratio of -46.79 (TTM) and a price-to-book (PB) ratio of 3.35, which is higher than the industry average PB of 3.42 [2] - International Medical is recognized for its contributions to the healthcare sector, receiving multiple awards, including being listed among the top 100 private hospitals in various categories [1] - The company is part of a competitive industry, with several peers showing varying PE ratios, indicating a challenging market environment [2]

Meeting Information - The 2024 Annual General Meeting (AGM) of Xi'an International Medical Investment Co., Ltd. is scheduled for May 15, 2025 [1][3] - The meeting will be conducted in a combined format of on-site voting and online voting [5] - The record date for shareholders to attend the meeting is May 12, 2025 [6] Attendance and Voting - All shareholders registered with China Securities Depository and Clearing Corporation Limited by the record date are entitled to attend the AGM [7] - Shareholders can appoint proxies to attend and vote on their behalf [7][8] - The online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system on the same day [4][19] Agenda and Proposals - The AGM will review several key proposals, including the annual reports from the Board of Directors and Supervisory Board, financial statements, profit distribution plan, and the reappointment of the auditing firm [16] - Proposal 8 requires a special resolution, needing approval from over two-thirds of the voting rights present at the meeting [12] Registration and Documentation - Registration for the meeting can be done in person or via fax/mail for distant shareholders [15][17] - Relevant documents and resolutions from previous board meetings are available for review [14][21]

证券代码：000516 证券简称：国际医学 公告编号：2025-019 西安国际医学投资股份有限公司 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司于 2025 年 4 月 23 日在《证券时报》《中国证券报》《上海证券报》 《证券日报》和巨潮资讯网上发布了《关于召开 2024 年度股东大会的通知》， 定于 2025 年 5 月 15 日召开 2024 年度股东大会。为进一步保护投资者的合法权 益，方便本公司股东行使股东大会表决权，现根据相关规定，发布关于召开公 司 2024 年度股东大会的提示性公告如下： 一、会议召开的基本情况 网络投票时间：2025 年 5 月 15 日。 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 5 月 15 日的交易时间，即 09:15—09:25，09:30—11:30 和 13:00— 15:00；通过深圳证券交易所互联网系统投票的具体时间为：2025 年 5 月 15 日 09:15—15:00 期间任意时间。 5.会议的召开方式：现场表决和网络投票相 ...